

# MAKING FIRST- AND SECOND-LINE TREATMENT DECISIONS FOR ADVANCED NSCLC

Chair: James Yang

**Sunday, 29 September, 13:00 – 14:30**

Hall 3, Salamanca Auditorium  
FIRA GRAN VIA  
BARCELONA, SPAIN

At this symposium, an international faculty of experts will discuss first-line treatment decisions for *EGFR* mutation-positive (*EGFR*M+) NSCLC and second-line treatment decisions for advanced NSCLC, including squamous cell carcinoma and non-oncogene addicted, non-squamous disease.

13:00 - 13:05

## Meeting Welcome and Introductions

**James Yang**

13:05 - 13:20

## Sequencing to Prolong the Chemotherapy-Free Period

**Barbara Melosky**

13:20 - 13:35

## Common Options for Uncommon Mutations

**James Yang**

13:35 - 13:45

## Panel Discussion: Choosing the First EGFR TKI for Advanced Non-Squamous NSCLC

**Moderator: James Yang**

13:45 - 14:00

## Squamous NSCLC: Where Do EGFR TKIs Fit In?

**Noemi Reguart**

14:00 - 14:15

## Non-Mutated, Non-Squamous NSCLC (Adenocarcinoma): Failing First-Line Immunotherapy + Chemotherapy, What Now? Treatment Options and the Role of the Angio-Immunogenic Switch

**Maximilian Hochmair**

14:15 - 14:25

## Panel Discussion: Choosing a Second-Line Treatment for Advanced NSCLC

**Moderator: James Yang**

14:25 - 14:30

## Meeting Close

**James Yang**

